company background image
ZRO

Biosenta CNSX:ZRO Stock Report

Last Price

CA$0.44

Market Cap

CA$10.1m

7D

10.0%

1Y

-12.0%

Updated

18 Aug, 2022

Data

Company Financials
ZRO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ZRO Stock Overview

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada.

Biosenta Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biosenta
Historical stock prices
Current Share PriceCA$0.44
52 Week HighCA$0.86
52 Week LowCA$0.065
Beta0.013
1 Month Change576.92%
3 Month Change-12.00%
1 Year Change-12.00%
3 Year Changen/a
5 Year Change340.00%
Change since IPO486.67%

Recent News & Updates

Shareholder Returns

ZROCA Household ProductsCA Market
7D10.0%2.9%1.3%
1Y-12.0%1.8%3.3%

Return vs Industry: ZRO underperformed the Canadian Household Products industry which returned 2.7% over the past year.

Return vs Market: ZRO underperformed the Canadian Market which returned 2.1% over the past year.

Price Volatility

Is ZRO's price volatile compared to industry and market?
ZRO volatility
ZRO Average Weekly Movementn/a
Household Products Industry Average Movement4.5%
Market Average Movement10.5%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.2%

Stable Share Price: Insufficient data to determine ZRO's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine ZRO's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986n/aAm Gillhttps://www.biosenta.com

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions.

Biosenta Fundamentals Summary

How do Biosenta's earnings and revenue compare to its market cap?
ZRO fundamental statistics
Market CapCA$10.14m
Earnings (TTM)-CA$3.92m
Revenue (TTM)CA$1.67k

6,286x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZRO income statement (TTM)
RevenueCA$1.67k
Cost of RevenueCA$8.81k
Gross Profit-CA$7.14k
Other ExpensesCA$3.91m
Earnings-CA$3.92m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin-426.54%
Net Profit Margin-234,117.57%
Debt/Equity Ratio-60.1%

How did ZRO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ZRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZRO?

Other financial metrics that can be useful for relative valuation.

ZRO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6834.1x
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does ZRO's PB Ratio compare to its peers?

ZRO PB Ratio vs Peers
The above table shows the PB ratio for ZRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.7x
FRDY Friday's Dog Holdings
0.7xn/aCA$7.8m
KPT KP Tissue
1.2x58.2%CA$106.3m
EMRG Emergence Global Enterprises
4.5xn/aCA$16.8m
CBD.U Hempfusion Wellness
0.3xn/aUS$5.7m
ZRO Biosenta
n/an/aCA$10.1m

Price-To-Book vs Peers: ZRO is good value based on its Price-To-Book Ratio (-4.3x) compared to the peer average (1.7x).


Price to Earnings Ratio vs Industry

How does ZRO's PE Ratio compare vs other companies in the North American Household Products Industry?

Price-To-Book vs Industry: ZRO is good value based on its Price-To-Book Ratio (-4.3x) compared to the North American Household Products industry average (3x)


Price to Book Ratio vs Fair Ratio

What is ZRO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZRO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-4.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZRO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ZRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZRO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZRO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of ZRO's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Biosenta regulatory filings.

Future Growth

How is Biosenta forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.9%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosenta has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of ZRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Biosenta competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Biosenta performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-40.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ZRO is currently unprofitable.

Growing Profit Margin: ZRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZRO is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.

Accelerating Growth: Unable to compare ZRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZRO is unprofitable, making it difficult to compare its past year earnings growth to the Household Products industry (-25.2%).


Return on Equity

High ROE: ZRO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Biosenta's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ZRO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ZRO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ZRO has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ZRO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZRO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ZRO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.2% each year


Discover healthy companies

Dividend

What is Biosenta current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZRO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ZRO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average board tenure


CEO

Am Gill

3.08yrs

Tenure

CA$454,070

Compensation

Mr. Amarvir Singh Gill, also known as Am, has been President and Chief Executive Officer at Biosenta Inc., since July 16, 2019 and its Director since November 1, 2016 and serves as its Interim Chief Financ...


CEO Compensation Analysis

Compensation vs Market: Am's total compensation ($USD351.47K) is above average for companies of similar size in the Canadian market ($USD185.51K).

Compensation vs Earnings: Insufficient data to compare Am's compensation with company performance.


Board Members

Experienced Board: ZRO's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.9%.


Top Shareholders

Company Information

Biosenta Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biosenta Inc.
  • Ticker: ZRO
  • Exchange: CNSX
  • Founded: 1986
  • Industry: Household Products
  • Sector: Household
  • Implied Market Cap: CA$10.138m
  • Shares outstanding: 23.04m
  • Website: https://www.biosenta.com

Location

  • Biosenta Inc.
  • 18 Wynford Drive
  • Suite 794
  • Toronto
  • Ontario
  • M3C 3S2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/18 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/03/31
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.